Latest News for: galapagos nv

Edit

Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight ...

GetNews 31 Mar 2025
Key companies developing therapies for Rheumatoid Arthritis are - Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, ...
Edit

Galapagos NV, - Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting (Galapagos NV)

Public Technologies 28 Mar 2025
) Galapagos NV Galapagos NV ... Statutory name Galapagos NV ... Galapagos NV published this content on March 27, 2025, and is solely responsible for the information contained therein.
Edit

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting

Pharmiweb 28 Mar 2025
Mechelen, Belgium; March 27, 2025, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ ... The proposed separation of Galapagos into two publicly traded entities is not included on the agenda of this AGM ... About Galapagos.
Edit

Mechelen, Belgium; (Form 6-K) (Galapagos NV)

Public Technologies 28 Mar 2025
Mechelen, Belgium; March 27, 2025, 21.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ ... About Galapagos ... Galapagos NV published this content on March 28, 2025, and is solely responsible for the information contained herein.
Edit

Galapagos NV Overview Voting Rights FINAL (Galapagos NV)

Public Technologies 27 Mar 2025
Op 27 maart 2025 bedraagt het totaal aantal aandelen en stemrechten van Galapagos NV 65.897.071 ... Galapagos NV published this ...
Edit

Galapagos publiceert 2024 jaarverslag en kondigt jaarlijkse Gewone Algemene Vergadering aan (Galapagos NV)

Public Technologies 27 Mar 2025
). Annual ... Third Quarter ... Disclaimer. Galapagos NV published this content on March 27, 2025, and is solely responsible for the information contained therein.
Edit

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting (Galapagos NV)

Public Technologies 27 Mar 2025
Mechelen, Belgium; March 27, 2025, 21.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ ... About Galapagos ... Galapagos NV published this content on March 27, 2025, and is solely responsible for the information contained therein.
Edit

Ulcerative Colitis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical trials, Medication, Therapies, Prevalence and ...

GetNews 27 Mar 2025
Gilead Sciences/Galapagos NV Rinvoq (Upadacitinib) & Skyrizi(Risankizumab) ... Takeda Pharmaceutical, Pfizer, Celgene (Bristol-Myers Squibb), Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, ...
Edit

Galapagos NV statutory accounts Fy 2024 EN 20.03.205 (Galapagos NV)

Public Technologies 27 Mar 2025
). F-cap 1 ... CODE. IDENTIFICATION DETAILS (at the filing date). NAME.. Galapagos Legal form 1. Public limited company Address ... 2800 ... DATE ... X ... Galapagos NV published this content on March 27, 2025, and is solely responsible for the information contained therein.
Edit

Statutory Auditors report Galapagos 2024 ENG unsigned (Galapagos NV)

Public Technologies 27 Mar 2025
GALAPAGOS NV ... STATUTORY AUDITOR'S REPORT TO THE GENERAL MEETING OF GALAPAGOS NV FOR THE YEAR ENDED 31 DECEMBER 2024 ... Galapagos NV published this content on March 27, 2025, and is solely responsible for the information contained therein.
Edit

Galapagos Annual Report 2024 1 (Galapagos NV)

Public Technologies 27 Mar 2025
Separation of Galapagos NV into two listed entities ... GalaRpiasgkosMNaV nagemeOn tJanuary 8, 2025, Galapagos NV ... Throughout this report, the term "Galapagos NV" refers solely to the non-con- rights and obligations under certain ... Galapagos NV.
Edit

GLPG Convening Notice ENG FINAL (Galapagos NV)

Public Technologies 27 Mar 2025
GALAPAGOS NV ... Galapagos NV ... Galapagos NV ... Galapagos NV ... The signed proxy form must be submitted to Galapagos by e-mail([email protected])or by mail (Galapagos NV, attn. ... Galapagos NV ... Galapagos NV .
Edit

Annual Report for Fiscal Year Ending 2024-12-31 (Form 20-F) (Galapagos NV)

Public Technologies 27 Mar 2025
On January 8, 2025, Galapagos NV ("Galapagos") announced that it entered into a separation agreement with Gilead pursuant to which Galapagos NV intends to spin-off a portion of its current ...
Edit

Axial Spondyloarthritis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | UCB ...

GetNews 25 Mar 2025
Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others.

Article Search

tools
×
×
×
×